Reuters logo
9 个月前
BRIEF-Genmab: FDA grants priority review for daratumumab
2016年10月10日 / 凌晨5点11分 / 9 个月前

BRIEF-Genmab: FDA grants priority review for daratumumab

1 分钟阅读

Oct 10 (Reuters) - Genmab A/S :

* U.S. FDA grants priority review for daratumumab in relapsed multiple myeloma

* The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of Feb. 17 to take a decision on daratumumab in this indication

* The PDUFA date for the combination of daratumumab with pomalidomide/dexamethasone is June 17, 2017 Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below